French drug giant Sanofi announced Monday US health authorities had rejected its Lemtrada drug for some forms of multiple sclerosis, which is already approved in the European Union, Canada and Australia.
The Food and Drug Administration (FDA) said Sanofi's subsidiary Genzyme, which makes the drug aimed at treating relapsing forms of the disease, had "not submitted evidence from adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects."
The FDA has also decided "one or more" clinical trials are necessary before approval of the drug—a move Sanofi said would likely prevent the drug from being approved on the US market by March 31 next year, as originally planned.
"We are extremely disappointed with the outcome of the review and the implications for patients in the US suffering with multiple sclerosis who remain in need of alternative therapies to manage a devastating disease," Genzyme President David Meeker said in a statement.
"Genzyme strongly disagrees with the FDA's conclusions and plans to appeal the agency's decision," the statement added.
Lemtrada is one of the most promising drugs in Sanofi's pipeline, and was a key motivation behind the French firm's 2011 takeover of Genzyme for more than $20 billion.
The drug is already approved in the European Union, Canada and Australia.
Multiple sclerosis, a degenerative disease of the nervous system which disrupts the brain's ability to communicate with the body, affects some 2.1 million people in the world, including 410,000 in the United States.
According to Sanofi, the most common side effects of Lemtrada include infections of the upper respiratory tract and urinary tract and lymphopenia—a reduction in the number of lymphocytes, a subset of white blood cells. Serious autoimmune conditions can also occur.
Explore further: US approves new multiple sclerosis capsules
© 2013 AFP
Medical Xpress on facebook
Related Stories
Sanofi-Aventis to buy Genzyme for $20.1 bln cash
Feb 16, 2011
(AP) -- French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the market ...
Sanofi-Aventis says gets US approval for Genzyme bid
Oct 20, 2010
French pharmaceutical giant Sanofi-Aventis said on Wednesday that US competition authorities had not raised any objections to its hostile bid for US biotechnology group and rare disease specialist Genzyme.
Aubagio approved for multiple sclerosis
Sep 13, 2012
(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).
US approves new multiple sclerosis capsules
Mar 27, 2013
The U.S. Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.
Genzyme board rejects Sanofi bid
Aug 30, 2010
The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday. ...
Recommended for you
Vaccine fears in China after hepatitis B scare
Dec 25, 2013
Chinese state-run media and Internet users demanded action Wednesday after the deaths of at least seven babies since November following their vaccinations against hepatitis B.
Tretten approved for genetic clotting disorder
Dec 23, 2013
(HealthDay)—Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.
Ariad to relaunch leukemia drug with new warnings (Update)
Dec 20, 2013
Ariad Pharmaceuticals has received approval to relaunch its leukemia drug Iclusig after addressing safety concerns raised by U.S. regulators in October.
Stent to treat pancreatic cysts approved
Dec 19, 2013
(HealthDay)—The Axios Stent and Delivery System has been approved by the U.S. Food and Drug Administration to treat infected pancreatic cysts that won't drain on their own and could become life threatening, the FDA said ...
The cost of antibiotic drugs for children—a comparison of two countries
Dec 19, 2013
The 2009 costs of antibiotics covered by private insurance companies in the U.S. for children younger than 10 years old were estimated to be more than five times higher than the costs in the United Kingdom (U.K.), which are ...
Bayer launches 1.9-bn-euro bid for Norway's Algeta
Dec 19, 2013
German pharmaceuticals giant Bayer said Thursday it has launched a 1.9-billion-euro ($2.6-billion) bid to buy Norwegian cancer treatment specialist Algeta.
User comments
© Medical Xpress 2011-2013, Science X network
French drug giant Sanofi announced Monday US health authorities had rejected its Lemtrada drug for some forms of multiple sclerosis, which is already approved in the European Union, Canada and Australia.
The Food and Drug Administration (FDA) said Sanofi's subsidiary Genzyme, which makes the drug aimed at treating relapsing forms of the disease, had "not submitted evidence from adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects."
The FDA has also decided "one or more" clinical trials are necessary before approval of the drug—a move Sanofi said would likely prevent the drug from being approved on the US market by March 31 next year, as originally planned.
"We are extremely disappointed with the outcome of the review and the implications for patients in the US suffering with multiple sclerosis who remain in need of alternative therapies to manage a devastating disease," Genzyme President David Meeker said in a statement.
"Genzyme strongly disagrees with the FDA's conclusions and plans to appeal the agency's decision," the statement added.
Lemtrada is one of the most promising drugs in Sanofi's pipeline, and was a key motivation behind the French firm's 2011 takeover of Genzyme for more than $20 billion.
The drug is already approved in the European Union, Canada and Australia.
Multiple sclerosis, a degenerative disease of the nervous system which disrupts the brain's ability to communicate with the body, affects some 2.1 million people in the world, including 410,000 in the United States.
According to Sanofi, the most common side effects of Lemtrada include infections of the upper respiratory tract and urinary tract and lymphopenia—a reduction in the number of lymphocytes, a subset of white blood cells. Serious autoimmune conditions can also occur.
Explore further: US approves new multiple sclerosis capsules
© 2013 AFP
Medical Xpress on facebook
Related Stories
Sanofi-Aventis to buy Genzyme for $20.1 bln cash
Feb 16, 2011
(AP) -- French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the market ...
Sanofi-Aventis says gets US approval for Genzyme bid
Oct 20, 2010
French pharmaceutical giant Sanofi-Aventis said on Wednesday that US competition authorities had not raised any objections to its hostile bid for US biotechnology group and rare disease specialist Genzyme.
Aubagio approved for multiple sclerosis
Sep 13, 2012
(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).
US approves new multiple sclerosis capsules
Mar 27, 2013
The U.S. Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.
Genzyme board rejects Sanofi bid
Aug 30, 2010
The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday. ...
Recommended for you
Vaccine fears in China after hepatitis B scare
Dec 25, 2013
Chinese state-run media and Internet users demanded action Wednesday after the deaths of at least seven babies since November following their vaccinations against hepatitis B.
Tretten approved for genetic clotting disorder
Dec 23, 2013
(HealthDay)—Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.
Ariad to relaunch leukemia drug with new warnings (Update)
Dec 20, 2013
Ariad Pharmaceuticals has received approval to relaunch its leukemia drug Iclusig after addressing safety concerns raised by U.S. regulators in October.
Stent to treat pancreatic cysts approved
Dec 19, 2013
(HealthDay)—The Axios Stent and Delivery System has been approved by the U.S. Food and Drug Administration to treat infected pancreatic cysts that won't drain on their own and could become life threatening, the FDA said ...
The cost of antibiotic drugs for children—a comparison of two countries
Dec 19, 2013
The 2009 costs of antibiotics covered by private insurance companies in the U.S. for children younger than 10 years old were estimated to be more than five times higher than the costs in the United Kingdom (U.K.), which are ...
Bayer launches 1.9-bn-euro bid for Norway's Algeta
Dec 19, 2013
German pharmaceuticals giant Bayer said Thursday it has launched a 1.9-billion-euro ($2.6-billion) bid to buy Norwegian cancer treatment specialist Algeta.
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment